<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399087</url>
  </required_header>
  <id_info>
    <org_study_id>Perifosine 105</org_study_id>
    <nct_id>NCT00399087</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Docetaxel With Perifosine</brief_title>
  <official_title>A Phase 1 Trial of the Combination of Perifosine and Docetaxel With or Without Prednisone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the drug perifosine given in combination with docetaxel. Perifosine is an&#xD;
      oral anti-cancer agent that has been used in more than 140 people. Docetaxel is a standard&#xD;
      chemotherapy agent used in many types of cancer. This study is designed to determine the&#xD;
      highest dose of perifosine that can be administered to people every day while they are&#xD;
      receiving docetaxel with or without a steroid called prednisone, without severe or prolonged&#xD;
      nausea, vomiting and diarrhea. This study starts with patients taking 50 mg/day and goes up&#xD;
      to 150 mg/day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, open-label trial of perifosine and docetaxel with or without prednisone in&#xD;
      patients with malignancies for whom single agent docetaxel is a reasonable treatment option.&#xD;
      All patients will receive docetaxel at a dose of 75 mg/m2 on day 8 of a 21-day cycle either&#xD;
      without (Arm A) or with prednisone 5 mg bid on days 1 - 21 (Arms B and C). (Patients on all&#xD;
      arms will receive premedication with dexamethasone around the time of docetaxel&#xD;
      administration either as described in the product insert for arm A or as used in prior&#xD;
      prostate cancer phase III studies for arm B and C. The 1st cohort of patients on Arm A and&#xD;
      Arm B will receive perifosine orally at a dose of 50 mg per day for the first 14 days of the&#xD;
      21-day cycle. On each arm, the perifosine dose will be escalated in subsequent groups to 50&#xD;
      mg bid and then 50 mg tid as tolerated. Alternating cohorts of 3 patients will be entered&#xD;
      first to Arm A and then to Arm B. At the completion of arms A and B, 3 cohorts of patients&#xD;
      will be entered who will receive perifosine weekly at doses of 900, 1200 and 1500 mg. The&#xD;
      total dose will be divided into 300 mg doses which will be delivered at least 4 hours apart.&#xD;
      The perifosine dose escalation for each arm will be performed separately according to the&#xD;
      following algorithm. For each arm, a maximum tolerated dose (MTD) will be defined as a dose&#xD;
      that can be given without grade 3/4 non-hematologic toxicity in more than 1/3 patients. If&#xD;
      2/3 patients in any cohort encounter a grade 3/4 non-hematologic toxicity, an additional 3&#xD;
      patients will be added. If the dose is intolerable for &gt;3/6 patients then the previous dose&#xD;
      level will be declared the MTD for that arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Perifosine D1 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perifosine D1+ Docexatel+Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perifosine+ D1,8 and 15+Docetaxel+Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perifosine</intervention_name>
    <description>Perifosine oral administration</description>
    <arm_group_label>Perifosine D1 + Docetaxel</arm_group_label>
    <arm_group_label>Perifosine D1+ Docexatel+Prednisone</arm_group_label>
    <arm_group_label>Perifosine+ D1,8 and 15+Docetaxel+Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV administration</description>
    <arm_group_label>Perifosine D1 + Docetaxel</arm_group_label>
    <arm_group_label>Perifosine D1+ Docexatel+Prednisone</arm_group_label>
    <arm_group_label>Perifosine+ D1,8 and 15+Docetaxel+Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Perifosine D1+ Docexatel+Prednisone</arm_group_label>
    <arm_group_label>Perifosine+ D1,8 and 15+Docetaxel+Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed diagnosis of cancer for&#xD;
             which treatment with single agent docetaxel would be an appropriate treatment option.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Patients may be currently receiving docetaxel using the schedule in the protocol, as&#xD;
             long as the treating investigator has reasonable expectation that the patient will&#xD;
             continue to receive docetaxel for 2 or more additional cycles. The current regimen&#xD;
             does not count towards the 2 regimens as long as the patient is not progressing on&#xD;
             therapy..&#xD;
&#xD;
          -  Patients must have a life expectancy of more than 3 months.&#xD;
&#xD;
          -  Patients must have a performance status of 0 to 2 according to the ECOG criteria.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined in the protocol:&#xD;
             leukocytes &gt;=4,000/microL, absolute neutrophil count &gt;=1,500/microL, platelets&#xD;
             &gt;=100,000/microL, HCT &gt; 28%, total bilirubin &lt; 1.5 x upper limit of normal, AST&#xD;
             (SGOT)/ALT (SGPT) &lt;=2.5 X institutional upper limit of normal, creatinine &lt;= 2.5 mg/dl&#xD;
&#xD;
          -  Patients must have recovered from acute toxicity related to prior therapy, excluding&#xD;
             alopecia, including surgery or radiotherapy.&#xD;
&#xD;
          -  Patients must be able to ingest oral medications.&#xD;
&#xD;
          -  Female patients who are pregnant or lactating are ineligible. All females of&#xD;
             childbearing potential must have a negative serum pregnancy test within 72 hours of&#xD;
             treatment. Men and women of childbearing potential must agree to employ adequate&#xD;
             contraception to prevent pregnancy while on therapy and for four weeks after the&#xD;
             completion of treatment.&#xD;
&#xD;
          -  Patients must have ability to understand and the willingness to sign a written&#xD;
             informed consent document.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents or devices.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to perifosine (miltefosine or edelfosine).&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection and psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  HIV-positive patients receiving combination anti-retroviral therapy are excluded from&#xD;
             the study because of possible pharmacokinetic interactions with perifosine.&#xD;
&#xD;
          -  Patients with a history of unstable or newly diagnosed angina pectoris, recent&#xD;
             myocardial infarction (within 6 months of enrollment) or New York Heart Assoc. class&#xD;
             II-IV congestive heart failure.&#xD;
&#xD;
          -  Patients with a history of hypersensitivity reaction to products containing&#xD;
             Polysorbate 80 (Tween 80).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 24, No 18S (June 20 Supplement), 2006: 13066</citation>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 10, 2006</study_first_submitted>
  <study_first_submitted_qc>November 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

